JP2009542591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009542591A5 JP2009542591A5 JP2009517003A JP2009517003A JP2009542591A5 JP 2009542591 A5 JP2009542591 A5 JP 2009542591A5 JP 2009517003 A JP2009517003 A JP 2009517003A JP 2009517003 A JP2009517003 A JP 2009517003A JP 2009542591 A5 JP2009542591 A5 JP 2009542591A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oral dosage
- solid oral
- dosage form
- acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 15
- 239000007787 solid Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 7
- 239000006186 oral dosage form Substances 0.000 claims 7
- 239000000583 progesterone congener Substances 0.000 claims 6
- 229940011871 estrogen Drugs 0.000 claims 5
- 239000000262 estrogen Substances 0.000 claims 5
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims 4
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 claims 4
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims 4
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims 4
- 229960004845 drospirenone Drugs 0.000 claims 4
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims 4
- 229960002568 ethinylestradiol Drugs 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- 229940022663 acetate Drugs 0.000 claims 3
- 238000005469 granulation Methods 0.000 claims 3
- 230000003179 granulation Effects 0.000 claims 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims 2
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 229960004400 levonorgestrel Drugs 0.000 claims 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims 1
- JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- ATXHVCQZZJYMCF-XUDSTZEESA-N Allylestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)CC=C)[C@@H]4[C@@H]3CCC2=C1 ATXHVCQZZJYMCF-XUDSTZEESA-N 0.000 claims 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 claims 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 claims 1
- LVHOURKCKUYIGK-RGUJTQARSA-N Dimethisterone Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 LVHOURKCKUYIGK-RGUJTQARSA-N 0.000 claims 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims 1
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 claims 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 claims 1
- YXYXCSOJKUAPJI-ZBRFXRBCSA-N [(8r,9s,13s,14s,17s)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfamate Chemical compound NS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 YXYXCSOJKUAPJI-ZBRFXRBCSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229960002692 allylestrenol Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960001616 chlormadinone acetate Drugs 0.000 claims 1
- 229960000978 cyproterone acetate Drugs 0.000 claims 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims 1
- 229960004976 desogestrel Drugs 0.000 claims 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims 1
- 229960003309 dienogest Drugs 0.000 claims 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims 1
- 229950006690 dimethisterone Drugs 0.000 claims 1
- 239000012738 dissolution medium Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 claims 1
- 229930182833 estradiol Natural products 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- 229950002007 estradiol benzoate Drugs 0.000 claims 1
- 229960004766 estradiol valerate Drugs 0.000 claims 1
- 229960003399 estrone Drugs 0.000 claims 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 claims 1
- 229960000445 ethisterone Drugs 0.000 claims 1
- CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 claims 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 claims 1
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims 1
- 238000009477 fluid bed granulation Methods 0.000 claims 1
- -1 guestden Chemical compound 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229960001910 lynestrenol Drugs 0.000 claims 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims 1
- 229960001786 megestrol Drugs 0.000 claims 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims 1
- 229960001390 mestranol Drugs 0.000 claims 1
- 229940053934 norethindrone Drugs 0.000 claims 1
- 229960001652 norethindrone acetate Drugs 0.000 claims 1
- 229960001858 norethynodrel Drugs 0.000 claims 1
- 229960000417 norgestimate Drugs 0.000 claims 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims 1
- 229960002831 norgestrienone Drugs 0.000 claims 1
- GVDMJXQHPUYPHP-FYQPLNBISA-N norgestrienone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)C#C)C=C3)C3=C21 GVDMJXQHPUYPHP-FYQPLNBISA-N 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 claims 1
- 229960001584 promegestone Drugs 0.000 claims 1
- QFFCYTLOTYIJMR-XMGTWHOFSA-N promegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)CC)(C)[C@@]1(C)CC2 QFFCYTLOTYIJMR-XMGTWHOFSA-N 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 229960001023 tibolone Drugs 0.000 claims 1
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06014002 | 2006-07-06 | ||
| PCT/EP2007/005764 WO2008003432A1 (en) | 2006-07-06 | 2007-06-29 | Pharmaceutical composition containing a tetrahydrofolic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009542591A JP2009542591A (ja) | 2009-12-03 |
| JP2009542591A5 true JP2009542591A5 (enExample) | 2010-08-19 |
Family
ID=36763829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009517003A Pending JP2009542591A (ja) | 2006-07-06 | 2007-06-29 | テトラヒドロ葉酸を含有する医薬組成物 |
Country Status (31)
| Country | Link |
|---|---|
| EP (2) | EP2040683B2 (enExample) |
| JP (1) | JP2009542591A (enExample) |
| KR (2) | KR20090033889A (enExample) |
| CN (3) | CN101489563A (enExample) |
| AR (2) | AR061958A1 (enExample) |
| AU (1) | AU2007271449B2 (enExample) |
| BR (1) | BRPI0713565B8 (enExample) |
| CA (2) | CA2656131C (enExample) |
| CL (1) | CL2007001962A1 (enExample) |
| CO (1) | CO6150125A2 (enExample) |
| CR (1) | CR10549A (enExample) |
| CU (1) | CU20090004A7 (enExample) |
| EC (1) | ECSP099030A (enExample) |
| ES (1) | ES2626838T5 (enExample) |
| GT (1) | GT200900001A (enExample) |
| IL (3) | IL196027A0 (enExample) |
| MA (1) | MA30598B1 (enExample) |
| MX (1) | MX2009000079A (enExample) |
| MY (1) | MY169516A (enExample) |
| NO (1) | NO347567B1 (enExample) |
| NZ (1) | NZ573766A (enExample) |
| PE (3) | PE20120375A1 (enExample) |
| PH (1) | PH12012501774B1 (enExample) |
| RU (2) | RU2479306C2 (enExample) |
| SG (1) | SG188869A1 (enExample) |
| TN (1) | TNSN08543A1 (enExample) |
| TW (2) | TWI508730B (enExample) |
| UA (2) | UA100228C2 (enExample) |
| UY (1) | UY30462A1 (enExample) |
| WO (1) | WO2008003432A1 (enExample) |
| ZA (4) | ZA200900868B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101489563A (zh) | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
| US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
| US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
| UY32836A (es) | 2009-08-12 | 2011-03-31 | Bayer Schering Pharma Ag | Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato |
| BR112012026115B1 (pt) | 2010-04-15 | 2019-12-24 | Bayer Ip Gmbh | forma de dosagem oral sólida, seu uso, e unidade de acondicionamento |
| US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
| AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
| US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| CN102516247A (zh) * | 2010-12-15 | 2012-06-27 | 连云港金康医药科技有限公司 | A型l-5-甲基四氢叶酸钙盐多晶型及其制备方法 |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| EP2781214A1 (en) * | 2013-03-22 | 2014-09-24 | Chemo Research, S.L. | Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca) |
| EP2878600B1 (en) | 2013-12-02 | 2018-06-27 | Cerbios-Pharma S.A. | Stable complexes of an alkaline earth metal salt of N5-methyl-tetrahydrofolic acid and a polyol |
| CN107812195B (zh) * | 2014-09-04 | 2021-04-20 | 连云港金康和信药业有限公司 | (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物 |
| JP6866560B2 (ja) | 2015-06-18 | 2021-04-28 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | エステトロール成分を含有する口腔内崩壊性投与単位 |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| JP6863547B2 (ja) | 2015-06-18 | 2021-04-21 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | エステトロール成分を含有する口腔内崩壊性投与単位 |
| MA44206B1 (fr) | 2015-06-18 | 2021-04-30 | Estetra Sprl | Comprimé orodispersible comprenant estetrol |
| CN105030779A (zh) * | 2015-07-21 | 2015-11-11 | 福格森（武汉）生物科技股份有限公司 | 一种(6s)-5-甲基四氢叶酸钙口服营养补充剂及其制备方法 |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| CN106336444A (zh) * | 2016-08-23 | 2017-01-18 | 国家卫生计生委科学技术研究所 | 一种新晶型炔雌醇 |
| CN107446458A (zh) * | 2017-08-04 | 2017-12-08 | 合众（佛山）化工有限公司 | 一种高耐水性的丙烯酸改性聚氨酯杂化树脂水性涂料 |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| CN110237046B (zh) * | 2019-03-29 | 2021-07-30 | 福格森（武汉）生物科技股份有限公司 | 一种l-5-甲基四氢叶酸微囊的制备方法 |
| CN110548034A (zh) * | 2019-07-12 | 2019-12-10 | 广州莎蔓生物科技有限公司 | 一种怀孕阻断药物 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| IT202100008834A1 (it) * | 2021-04-08 | 2022-10-08 | Ind Chimica Srl | Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina |
| CN114569567B (zh) * | 2021-12-20 | 2023-03-14 | 南通联亚药业股份有限公司 | 一种稳定的双醋炔诺酮炔雌醇复方片及其制备方法 |
| CN115813937B (zh) * | 2022-12-01 | 2025-04-11 | 南通联亚药业股份有限公司 | 一种稳定的包含屈螺酮和雌二醇的药物组合物及其制备方法 |
| WO2025132557A1 (en) * | 2023-12-20 | 2025-06-26 | Lesaffre Et Compagnie | Solid formulations of tetrahydrofolates |
| CN117771389A (zh) * | 2023-12-28 | 2024-03-29 | 浙江圣达生物药业股份有限公司 | L-5-甲基四氢叶酸钙-γ-环糊精包合物及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3347125A1 (de) | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption |
| FR2676927B1 (fr) * | 1991-05-29 | 1995-06-23 | Ibf | Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant. |
| TW390813B (en) * | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
| DE4426709A1 (de) | 1994-07-20 | 1996-01-25 | Schering Ag | Steroidale Sexualhormone enthaltende feste Arzneiformen |
| KR100384264B1 (ko) * | 1994-09-22 | 2003-08-30 | 악조 노벨 엔.브이. | 습식과립화에의한 투여단위의제조방법 |
| RU2073529C1 (ru) * | 1995-05-16 | 1997-02-20 | Центральный научно-исследовательский рентгенорадиологический институт | Композиция для эмболизации кровеносных сосудов |
| CH693255A5 (de) | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
| CN1240387C (zh) * | 1998-04-17 | 2006-02-08 | 奥索一麦克尼尔药品公司 | 含有叶酸的药用组合物及其用途和给药系统 |
| US6214815B1 (en) * | 1998-12-23 | 2001-04-10 | Ortho-Mcneil Pharmaceuticals, Inc. | Triphasic oral contraceptive |
| CH693905A5 (de) | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
| CA2382426C (en) * | 1999-08-31 | 2006-02-28 | Schering Aktiengesellschaft | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
| RS50262B2 (sr) * | 1999-08-31 | 2018-10-31 | Bayer Pharma AG | Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva |
| ATE442147T1 (de) * | 2000-01-18 | 2009-09-15 | Bayer Schering Pharma Ag | Pharmazeutische zubereitung enthaltend drospirenon |
| US6550482B1 (en) * | 2000-04-21 | 2003-04-22 | Vascular Control Systems, Inc. | Methods for non-permanent occlusion of a uterine artery |
| US6864774B2 (en) | 2000-10-19 | 2005-03-08 | Matsushita Electric Industrial Co., Ltd. | Inductance component and method of manufacturing the same |
| EP1216712A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Cyclodextrin-drospirenone inclusion complexes |
| EP1216713A1 (en) * | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| US6537569B2 (en) * | 2001-02-14 | 2003-03-25 | Microvention, Inc. | Radiation cross-linked hydrogels |
| RS50909B (sr) * | 2002-02-21 | 2010-08-31 | Bayer Schering Pharma Aktiengesellschaft | Farmaceutske kompozicije koje se sastoje od jednog ili više steroida, jedne ili više tetrahidrofolatne komponente i vitamina b12 |
| US20060069168A1 (en) * | 2002-10-29 | 2006-03-30 | Norikazu Tabata | Vascular embolization material |
| UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
| MX2009000256A (es) * | 2006-07-06 | 2009-02-18 | Bayer Schering Pharma Ag | Preparaciones farmaceuticas para la anticoncepcion y para prevenir el riesgo de malformaciones congenitas. |
| CN101489563A (zh) | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
| RU62008U1 (ru) * | 2006-10-13 | 2007-03-27 | Закрытое акционерное общество "ААА-КОМПАНИ" | Средство для эмболизации сосудов |
| RU61120U1 (ru) * | 2006-10-13 | 2007-02-27 | Закрытое акционерное общество "ААА-КОМПАНИ" | Средство для эмболизации сосудов |
| US8916188B2 (en) * | 2008-04-18 | 2014-12-23 | Abbott Cardiovascular Systems Inc. | Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block |
-
2007
- 2007-05-05 CN CNA2007800254913A patent/CN101489563A/zh active Pending
- 2007-06-21 MY MYPI20070991A patent/MY169516A/en unknown
- 2007-06-25 TW TW096122889A patent/TWI508730B/zh active
- 2007-06-25 TW TW104122823A patent/TW201538161A/zh unknown
- 2007-06-29 CN CN2007800255704A patent/CN101484143B/zh active Active
- 2007-06-29 UA UAA200900637A patent/UA100228C2/uk unknown
- 2007-06-29 CN CN201210143925.2A patent/CN102813663B/zh active Active
- 2007-06-29 NZ NZ573766A patent/NZ573766A/en unknown
- 2007-06-29 WO PCT/EP2007/005764 patent/WO2008003432A1/en not_active Ceased
- 2007-06-29 EP EP07764936.6A patent/EP2040683B2/en active Active
- 2007-06-29 ES ES07764936T patent/ES2626838T5/es active Active
- 2007-06-29 RU RU2009103649/15A patent/RU2479306C2/ru active
- 2007-06-29 NO NO20090578A patent/NO347567B1/no unknown
- 2007-06-29 UA UAA201207425A patent/UA105078C2/uk unknown
- 2007-06-29 KR KR1020097002386A patent/KR20090033889A/ko not_active Ceased
- 2007-06-29 CA CA2656131A patent/CA2656131C/en not_active Expired - Fee Related
- 2007-06-29 JP JP2009517003A patent/JP2009542591A/ja active Pending
- 2007-06-29 EP EP11190550.1A patent/EP2422774B1/en not_active Revoked
- 2007-06-29 MX MX2009000079A patent/MX2009000079A/es active IP Right Grant
- 2007-06-29 CA CA2856344A patent/CA2856344C/en not_active Expired - Fee Related
- 2007-06-29 BR BRPI0713565A patent/BRPI0713565B8/pt active IP Right Grant
- 2007-06-29 SG SG2013017165A patent/SG188869A1/en unknown
- 2007-06-29 KR KR1020137006954A patent/KR20130042638A/ko not_active Ceased
- 2007-06-29 AU AU2007271449A patent/AU2007271449B2/en active Active
- 2007-07-04 UY UY30462A patent/UY30462A1/es not_active Application Discontinuation
- 2007-07-05 PE PE2011002146A patent/PE20120375A1/es active IP Right Grant
- 2007-07-05 CL CL2007001962A patent/CL2007001962A1/es unknown
- 2007-07-05 PE PE2014002543A patent/PE20150287A1/es active IP Right Grant
- 2007-07-05 PE PE2007000867A patent/PE20080273A1/es not_active Application Discontinuation
- 2007-07-06 AR ARP070103016A patent/AR061958A1/es not_active Application Discontinuation
-
2008
- 2008-12-18 IL IL196027A patent/IL196027A0/en active IP Right Grant
- 2008-12-31 TN TNP2008000543A patent/TNSN08543A1/en unknown
-
2009
- 2009-01-05 EC EC2009009030A patent/ECSP099030A/es unknown
- 2009-01-06 CO CO09000752A patent/CO6150125A2/es unknown
- 2009-01-06 GT GT200900001A patent/GT200900001A/es unknown
- 2009-01-06 CU CU2009000004A patent/CU20090004A7/es active IP Right Grant
- 2009-01-06 CR CR10549A patent/CR10549A/es not_active Application Discontinuation
- 2009-01-23 MA MA31584A patent/MA30598B1/fr unknown
- 2009-02-05 ZA ZA2009/00868A patent/ZA200900868B/en unknown
-
2012
- 2012-08-02 RU RU2012133154A patent/RU2624236C2/ru active
- 2012-09-06 PH PH12012501774A patent/PH12012501774B1/en unknown
-
2013
- 2013-01-30 IL IL224484A patent/IL224484A/en active IP Right Grant
-
2015
- 2015-03-11 ZA ZA2015/01673A patent/ZA201501673B/en unknown
-
2016
- 2016-04-21 IL IL245355A patent/IL245355B/en active IP Right Grant
- 2016-11-03 AR ARP160103347A patent/AR106561A2/es not_active Application Discontinuation
-
2018
- 2018-11-29 ZA ZA2018/08084A patent/ZA201808084B/en unknown
- 2018-11-29 ZA ZA2018/08083A patent/ZA201808083B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009542591A5 (enExample) | ||
| RU2012133154A (ru) | Фармацевтическая композиция, содержащая тетрагидрофолиевую кислоту | |
| KR102265150B1 (ko) | 에스테트롤 성분을 함유하는 구강 붕해성 고체 투여 단위 | |
| JP5810159B2 (ja) | ドロスピレノンを含む医薬組成物及び避妊用キット | |
| JP5883810B2 (ja) | プロゲストゲン及び／又はエストロゲン及び５−メチル−（６ｓ）−テトラヒドロフォレートを含んで成る医薬組成物 | |
| JP2013166753A5 (enExample) | ||
| JP6866560B2 (ja) | エステトロール成分を含有する口腔内崩壊性投与単位 | |
| JP2004518656A5 (enExample) | ||
| JP2008540482A5 (enExample) | ||
| US12318395B2 (en) | Ethinyl estradiol-β-cyclodextrin complex and process for preparing thereof | |
| CN102198108A (zh) | 一种盐酸西那卡塞片剂或胶囊制备工艺 | |
| JP2008518895A5 (enExample) | ||
| CN102274235B (zh) | 一种新的避孕药物组合及制备方法 | |
| ES2777886T3 (es) | Composición farmacéutica que comprende drospirenona y kit anticonceptivo | |
| CN102188426A (zh) | 能够降低皮肤潮红的烟酸制剂 | |
| CN103976970A (zh) | 美他多辛缓释片的制备方法 | |
| CN102349882A (zh) | 一种含有群多普利的药物组合物及其制备方法 | |
| ES2511841T3 (es) | Gestágeno en combinación con uno o varios coadyuvantes/soportes farmacéuticamente aceptables para la contracepción oral exenta de lactosa | |
| JPWO2020120548A5 (enExample) | ||
| PL203449B1 (pl) | Kompozycja zawieraj aca kompleks estrogenu z cyklodekstryn a, sposób jej wytwarzania oraz zastosowanie kompleksu i kompozycji |